dr. smith on using venetoclax versus ibrutinib in cll
Published 4 years ago • 569 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:31
dr. smith on the rationale behind the fixed duration trial for ibrutinib/venetoclax in cll
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
1:51
dr. smith on frontline treatment considerations in cll
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
1:09
dr. byrd on long-term safety data with ibrutinib in cll
-
3:01
ibrutinib venetoclax for cll
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
0:54
dr. davids discusses ongoing research with ibrutinib plus venetoclax in cll
-
0:56
dr. al-sawaf on continual mrd assessment after venetoclax/obinutuzumab in cll
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
1:14
dr. smith on utilizing lenalidomide in cll
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
24:09
update on venetoclax for cll
-
1:41
dr. jacobs on the use of ibrutinib in high-risk patients with cll
-
0:47
dr. davids on remaining questions with umbralisib/ibrutinib in cll and mcl
-
1:36
dr. logan discusses ibrutinib plus venetoclax in cll